Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL29564721 | 1.00 | — | — | |
| SCHEMBL136333 | 0.98 | DRD2 (0.50) | — | |
| SCHEMBL7879783 | 0.98 | DRD2 (0.50) | — | |
| SCHEMBL12610007 | 0.83 | — | — | |
| SCHEMBL12610008 | 0.83 | — | — | |
| Hydrochloric Acid SCHEMBL15111523 | 0.82 | — | — | |
| Hydrochloric Acid SCHEMBL16443901 | 0.82 | — | — | |
| Hydrochloric Acid SCHEMBL16443782 | 0.82 | — | — | |
| Hydrochloric Acid SCHEMBL917502 | 0.81 | DRD2 (0.53) | — | |
| Hydrochloric Acid SCHEMBL3653333 | 0.81 | DRD2 (0.53) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8592417-B2 | 2-substituted-6-heterocyclic pyrimidone derivatives as tau protein kinase 1 inhibitors | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2013-11-26 | — | — | US | disclosed |
| US-8518939-B2 | 6-pyrimidinyl-pyrimid-4-one derivative | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2013-08-27 | — | — | US | disclosed |
| EP-2193129-B1 | 6-PYRIMIDINYL-PYRIMID-2-ONE DERIVATIVE | MITSUBISHI TANABE PHARMA CORP (JP) | 2012-10-24 | — | — | EP | disclosed |
| US-20120252812-A1 | 6-PYRIMIDINYL-PYRIMID-4-ONE DERIVATIVE | SANOFI-AVENTIS (FR) | 2012-10-04 | — | — | US | disclosed |
| EP-2097409-B1 | 2-SUBSTITUTED-6-HETEROCYCLIC PYRIMIDONE DERIVATIVES AS TAU PROTEIN KINASE 1 INHBITORS | MITSUBISHI TANABE PHARMA CORP (JP) | 2012-09-12 | — | — | EP | disclosed |
| US-8198437-B2 | 6-pyrimidinyl-pyrimid-4-one derivative | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2012-06-12 | — | — | US | disclosed |
| US-20110021773-A1 | 6-PYRIMIDINYL-PYRIMID-4-ONE DERIVATIVE | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2011-01-27 | — | — | US | disclosed |
| EP-2193129-A1 | 6-PYRIMIDINYL-PYRIMID-2-ONE DERIVATIVE | Mitsubishi Tanabe Pharma Corporation (JP) | 2010-06-09 | — | — | EP | disclosed |
| US-20100113775-A1 | 2-SUBSTITUTED-6-HETEROCYCLIC PYRIMIDONE DERIVATIVES AS TAU PROTEIN KINASE 1 INHIBITORS | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2010-05-06 | — | — | US | disclosed |
| EP-2097409-A1 | 2-SUBSTITUTED-6-HETEROCYCLIC PYRIMIDONE DERIVATIVES AS TAU PROTEIN KINASE 1 INHBITORS | Mitsubishi Tanabe Pharma Corporation (JP) | 2009-09-09 | — | — | EP | disclosed |
| EP-2078717-A1 | 6-Pyrimidinyl-pyrimid-2-one derivative | sanofi-aventis (FR) | 2009-07-15 | — | — | EP | disclosed |
| WO-2009035162-A1 | 6-PYRIMIDINYL-PYRIMID-2-ONE DERIVATIVE | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-03-19 | — | — | WO | disclosed |
| WO-2008078837-A1 | 2-SUBSTITUTED-6-HETEROCYCLIC PYRIMIDONE DERIVATIVES AS TAU PROTEIN KINASE 1 INHBITORS | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2008-07-03 | — | — | WO | disclosed |